The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Maria Karlsson Osipova, DNB Carnegie . Maria.Karlsson.Osipova@dnbcarnegie.se

  Year-End Report 25/26, October 7, 2026

I am pleased to share encouraging news regarding our retogatein (GAD-alum) drug candidate. A peer-reviewed publication in Diabetologia reported that retogatein may delay progression from early, non-insulin-requiring Type 1 Diabetes (Stage 1 and 2 T1D) to insulin-requiring Stage 3 disease by more than five years in a genetically defined subgroup.

The past year has been one of challenges, discipline, and renewed focus for Diamyd Medical. Following the decision to close the DIAGNODE-3 study, we acted decisively to reduce costs, preserve our financial strength, and reassess where we believe the company can create the greatest shareholder value.

Calendar

  
Data pager
Data pager
12
December 3, 2026
Annual General Meeting
Annual General Meeting 2026
January 26, 2027
Interim report Q1
Interim report Q1 2026/27
March 24, 2027
10th ASIT Summit, Boston, USA
April 27, 2027
Interim report Q2
Interim report Q2 2026/27

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd Medical team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
 

Diamyd Medical

Developing precision medicine therapies for the prevention and treatment of autoimmune diabetes

 

Ten largest shareholders as of September 30, 2026

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 18 417 734 11.88 9.87
Nordnet Pensionsförsäkring 12 471 869 8.05 6.69
Lindkvist, Bertil 10 200 000 6.58 5.47
Essen-Möller, Anders * 1 235 620 5 797 192 4.54 9.73
Vestal Point Capital LP 2 111 386 1.36 1.13
RA Capital Management LP 2 051 760 1.32 1.10
Point 72 Asset Management 2 022 864 1.31 1.08
Mats Carlsson 1 369 760 0.88 0.73
Essen-Möller, Maria-Teresa 400 000 963 998 0.88 2.66
Mattias Löfgren 1 026 592 0.66 0.55
Remaining shareholders 1 867 500 95 048 225 62.53 60.97
Total 3 503 120 151 481 380 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS